Will Cabozantinib enter medical insurance in 2023?

Cabozantinib (Cabozantinib) is an oral targeted therapy drug that is a multi-target tyrosine kinase inhibitor. It is mainly used to treat certain types of cancer, especially renal cell carcinoma (kidney cancer) and thyroid cancer. Cabozantinib, as a targeted drug, exerts anti-cancer effects by inhibiting the activity of multiple receptor kinases and interfering with the proliferation, angiogenesis and metastasis of tumor cells.

Cabozantinib inhibits the activity of multiple receptor kinases, including key receptor kinases such as vascular endothelial growth factor receptor (VEGFR), hepatocyte growth factor receptor (MET), platelet-derived growth factor receptor (PDGFR). These receptor kinases play important roles in tumor cell proliferation, angiogenesis, and metastasis. By inhibiting the activity of these receptor kinases, cabozantinib blocks signaling pathways and inhibits the growth and spread of tumor cells.

Cabozantinib, as a targeted drug, provides a new treatment option for some patients with advanced or refractory cancer. However, patients should consult a professional doctor before using the drug to ensure the suitability and safety of the drug, and follow the doctor's prescriptions and recommendations. At the same time, it is very important to conduct regular medical examinations and follow-up during the medication period to monitor the efficacy and deal with possible side effects.

Cabozantinib is not currently on the market in China, and therefore is not included in medical insurance. Therefore, patients cannot purchase it domestically and need to purchase it through overseas channels. There are original and generic drugs of cabozantinib abroad. The original drugs are mainly Japanese original drugs, Turkish original drugs and European version of original drugs. Foreign generic drugs are mainly Lao generic drugs and Bangladeshi generic drugs, with prices ranging from 1,300 to 2,700 yuan, and the ingredients of original drugs and generic drugs are basically the same.